References
- Martin PY, Gines PR, Schrier W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533–41
- Sessa W. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131–43
- Clemens MG. Nitric oxide in liver injury. Hepatology 1999; 30: 1–5
- Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–5
- MacAllister R, Whitley G, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathway. Kidney Int 1994; 45: 737–42
- Siroen MP, van der Sijp JRM, Teerlink T, van Schaik C, Nijveldt RJ, van Leeuwen PA. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 2005; 41: 559–65
- Lluch P, Torondel B, Medina P, Segarra G, del Olmo JA, Serra MA, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004; 41: 55–9
- Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frolich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology 2003; 38: 1063–4
- Nijveldt RJ, Teerlink T, van Leeuwen PA. The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin Nutr 2003; 22: 99–104
- Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, del Olmo JA, et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med 2006; 231: 70–5
- Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007; 45: 62–71
- Majano PL, Garcia-Monzon C. Does nitric oxide play a pathogenic role in hepatitis C virus infection?. Cell Death Differ 2007; 10: S13–15
- Amaro MJ, Bartolome J, Pardo M, Cotonat T, Lopez-Farre A, Carreño V. Decreased nitric oxide production in chronic viral hepatitis B and C. J Med Virol 1997; 51: 326–331
- Hokari A, Zeniya M, Esumi H, Ishikawa T, Kurasima Y, Toda G. Role of nitric oxide (NO) in interferon-alpha therapy for hepatitis C. J Infection 2005; 51: 47–53
- Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409–17
- Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Whitley IG, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343: 209–14
- Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG, NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264: 10205–9
- Kimoto M, Tsuji H, Ogawa T, Sasaoka K. Detection of NG, NG-dimethylarginine dimethylaminohidrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch Biochem Biophys 1993; 300: 657–62
- Fleck C, Janz A, Scheweitzer F, Karge E, Schewertfeger M, Stein G. Serum concentration of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int 2001; 78(suppl)S14–8
- Sharara AI, Perkins DJ, Misukonis MA, Chan SU, Dominitz JA, Weinberg JB. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. J Exper Med 1997; 186: 1495–502
- Mihm S, Fayyazi A, Ramadori G. Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury. Hepatology 1997; 26: 451–8
- Ersoy Y, Bayraktar NM, Mizrak B, Ozerol IH, Gunal S, Aladag M, et al. The level of endothelin-1 and nitric oxide in patients with chronic viral hepatitis B and C and correlation with histopathological grading and staging. Hepatol Res 2006; 34: 111–6
- George M, Baluch M, Van Thiel DH. Plasma and hepatic tissue levels of thrombomodulin, tissue factor, NF(B and nitric oxide in responders and nonresponders to INF( therapy. J Viral Hepatitis 2003; 10: 360–6